It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%’ (LBA52) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What have been the challenges of using immune checkpoint inhibitor monotherapies in the first-line treatment of non-small cell lung cancer (NSCLC)? (0:05)
- What were the aims, design and eligibility criteria of the EMPOWER-Lung 1 study? (1:43)
- What were the efficacy and safety findings of the study? (2:59)
- What will be the impact of these findings on clinical practice? (3:56)
- What will be the next step in the clinical development of cemiplimab? (4:20)
Speaker Disclosures: Dr Ahmet Sezer has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. The EMPOWER-Lung 1 study was funded by Regeneron Pharmaceuticals, Inc. and Sanofi.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Lung Cancer
Paula Ugalde, WCLC 2021: Screening, Incidental Nodules, and Adjuvant Therapy for Early-Stage Lung Cancer
touchONCOLOGY joins Dr Paula Ugalde (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) at WCLC 2021 to discuss her presentation on screening, incidental nodules and adjuvant therapy for early-stage lung cancer. Questions 1. Early detection of lung cancer improves disease outcomes – when and in which patients do you perform screening? (00:15-00:46) 2. […]
Antoinette Wozniak, WCLC 2021: Important Recent Developments in the Diagnosis and Management of Small Cell Lung Cancer
touchONCOLOGY joins Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss the challenges of treating small cell lung cancer and the most important recent advances. Questions 1. Please can you outline the current prognosis for patients with small cell lung cancer (SCLC)? (00:26-02:37) 2. In your opinion, what are […]
Antoinette Wozniak, WCLC 2021: Highlights of the digital 2021 conference
touchONCOLOGY joins Editorial Board Member Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss her highlights of the conference this year. Question What have been your particular highlights of the World Conference on Lung Cancer 2021? Disclosures: Antoinette Wozniak has no financial or non-financial conflicts of interest to declare […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!